Andere Sprachen Intellia Therapeutics, Inc.

Aktien

A2AG6H

US45826J1051

NTLA

Biotechnologie

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 16.06.2026			Vorbörslich 15:02:52
14,55 ^USD	-2,48 %		14,48	-0,45 %

13.06.	Intellia Therapeutics berichtet über weitere positive Phase-3-Ergebnisse für Lonvoguran Ziclumeran bei Patienten mit hereditärem Angioödem	CI
13.05.	Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM

Andere Sprachen

13.06.	Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
13.06.	Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
05.06.	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01.06.	Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
11.05.	Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
11.05.	Intellia Therapeutics Q1 Loss Narrows, Revenue Falls
11.05.	Earnings Flash (NTLA) Intellia Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.91 Loss
11.05.	Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q1 Revenue $15.0M, vs. FactSet Est of $13.8M
11.05.	Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
05.05.	Intellia Therapeutics to Participate in Upcoming Investor Conferences
04.05.	Intellia Initiates Rolling BLA Submission For In Vivo CRISPR Therapy In Hereditary Angioedema
01.05.	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29.04.	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
27.04.	Intellia Therapeutics Launches $150 Million Stock Offering
27.04.	Intellia Therapeutics, Inc. has filed an IPO.
27.04.	Intellia Announces Proposed Public Offering of Common Stock
27.04.	Intellia Therapeutics Starts Rolling FDA Application After Phase 3 Angioedema Trial Meets Primary Endpoint
27.04.	Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial
27.04.	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
27.04.	Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27.04.	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27.04.	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to Fda for Lonvoguran Ziclumeran as A One-Time Treatment for Hereditary Angioedema
27.04.	Intellia Therapeutics Reports Positive Phase 3 Results In Hereditary Angioedema
24.04.	Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
03.04.	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)